THE GLOBAL PROTON THERAPY MARKET WILL REACH US$ 2.2 BILLION IN 2032, GROWING BY 9% ANNUALLY.
Today there are 39 proton therapy facilities for a total of 106 treatment rooms treating patients around the world, representing merely 0.8% of all conventional radiotherapy systems. By 2017 there will be 255 operational proton therapy treatment rooms. Proton therapy remains a niche market however it is just up-and-coming and growing fast. It has been subject to substantial interest in the past decade and significant growth in proton treatment facilities around the world is expected in the foreseeable future. In 2011, the global proton therapy devices market reached US$ 350 million. We project the global addressable market at 1,000 particle therapy treatment rooms, valued at US$ 2.2 billion (including services) by 2032, showing an average annual growth of 9% from 2011 to 2032.
IBA clearly dominated the world market for the past 20 years. However for several years, other vendors, such as Varian, have been increasing their market share. For the year 2017, we estimate that IBA will hold just over 30% of the world particle therapy market, followed by Varian with 15% and by Mitsubishi and Hitachi holding a 9% market share each. The three Japanese particle therapy manufacturers, while mostly active in Japan for the past two decades, are now developing their strategies to be more active worldwide.
Information sheet including table of contents
©
Today there are 39 proton therapy facilities for a total of 106 treatment rooms treating patients around the world, representing merely 0.8% of all conventional radiotherapy systems. By 2017 there will be 255 operational proton therapy treatment rooms. Proton therapy remains a niche market however it is just up-and-coming and growing fast. It has been subject to substantial interest in the past decade and significant growth in proton treatment facilities around the world is expected in the foreseeable future. In 2011, the global proton therapy devices market reached US$ 350 million. We project the global addressable market at 1,000 particle therapy treatment rooms, valued at US$ 2.2 billion (including services) by 2032, showing an average annual growth of 9% from 2011 to 2032.
IBA clearly dominated the world market for the past 20 years. However for several years, other vendors, such as Varian, have been increasing their market share. For the year 2017, we estimate that IBA will hold just over 30% of the world particle therapy market, followed by Varian with 15% and by Mitsubishi and Hitachi holding a 9% market share each. The three Japanese particle therapy manufacturers, while mostly active in Japan for the past two decades, are now developing their strategies to be more active worldwide.
Information sheet including table of contents
©
